Hanna Sanoff

16PUBLICATIONS
106CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer diagnosisPredictive and prognostic markersDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 29, 2026
COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

|Jan 13, 2026
Ensuring the Future of Cooperative Group Cancer Clinical Trials: A Call for Comprehensive Support and Prioritization.

Christopher H Lieu, Hanna K Sanoff

|Oct 17, 2025
Community-Engaged Approach to Increase Physical Activity Among Black Individuals With Colorectal Cancer: Protocol for a Feasibility Randomized Controlled Trial of the Physical Activity Centers Empowerment Study.

Rachel Hirschey, Jingle Xu, Nathaniel Woodard

|Sep 02, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

Rishi Surana, Micaela Morgado, Ashwin Somasundaram

|Sep 19, 2024
Putting IDEA's Results Into Practice: Practicality Should Rule Complexity in Stage III Colon Cancer.

Hanna K Sanoff

|Jun 05, 2024
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.

Hanna K Sanoff, Allison M Deal, Jai Patel

Pageof 3

Frequent Collaborators

2 joint publications

Grant R Williams

2 joint publications

Theodore S Hong

2 joint publications

Ethan M Basch

2 joint publications

Allison M Deal